$5.66
7.40% yesterday
NYSE, Nov 25, 10:17 pm CET
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Amylyx Pharmaceuticals Stock price

$5.66
+0.35 6.59% 1M
+3.93 227.17% 6M
-9.06 61.55% YTD
-7.27 56.23% 1Y
-12.41 68.68% 3Y
-12.41 68.68% 5Y
-12.41 68.68% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.39 7.40%
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Key metrics

Market capitalization $387.98m
Enterprise Value $156.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.79
P/S ratio (TTM) P/S ratio 1.97
P/B ratio (TTM) P/B ratio 1.98
Revenue growth (TTM) Revenue growth -33.22%
Revenue (TTM) Revenue $196.49m
EBIT (operating result TTM) EBIT $-213.09m
Free Cash Flow (TTM) Free Cash Flow $-95.58m
Cash position $234.40m
EPS (TTM) EPS $-3.82
P/E forward negative
P/S forward 4.41
EV/Sales forward 1.78
Short interest 2.07%
Show more

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Amylyx Pharmaceuticals forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
50%
Hold
50%

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
196 196
33% 33%
100%
- Direct Costs 135 135
580% 580%
69%
61 61
78% 78%
31%
- Selling and Administrative Expenses 148 148
16% 16%
76%
- Research and Development Expense 125 125
19% 19%
64%
-212 -212
3,037% 3,037%
-108%
- Depreciation and Amortization 1.05 1.05
8% 8%
1%
EBIT (Operating Income) EBIT -213 -213
2,658% 2,658%
-108%
Net Profit -259 -259
14,202% 14,202%
-132%

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Positive
Seeking Alpha
about 17 hours ago
The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may...
Neutral
Seeking Alpha
17 days ago
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Chief Executive Officer Conference Call Participants Charlie Yang - B...
Neutral
Business Wire
19 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results.
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Josh Klee
Employees 384
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today